RxDoctor Payments Data

Manuel Gonzalez, MD

Internal Medicine · Miami, FLNPI 1356584361

Payments from drug & device makers

$579,030in general payments, 2019–2025

Across 72 payments — averaging $8042.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Inc.$477K
  • Mylan Technologies Inc.$93K
  • AstraZeneca$8K
  • Novo Nordisk$372
  • Abbott$171
  • Sunovion Pharmaceuticals Inc.$93
  • plus $382 from 11 others

What the payments were for

  • Food & beverage$1,126100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$579,030 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$31,045
Medicare patients
63
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol105$81,300
XareltoRivaroxaban90$60,178
EliquisApixaban92$59,215
TradjentaLinagliptin92$51,418
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$39,215
MounjaroTirzepatide25$31,837
EntrestoSacubitril/Valsartan38$29,225
JardianceEmpagliflozin36$27,800
OzempicSemaglutide14$21,005
Spiriva RespimatTiotropium Bromide26$13,168
JanuviaSitagliptin Phosphate18$12,462
Lantus SolostarInsulin Glargine,hum.Rec.Anlog94$8,860
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$4,001
Nifedipine ErNifedipine80$3,700
Atorvastatin Calcium589$3,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$8,143$81,300105 claims
Johnson & JohnsonXarelto$33$60,17890 claims
GSKTrelegy Ellipta$23$39,21557 claims
Lilly USA, LLCMounjaro$15$31,83725 claims
Novo NordiskOzempic$372$21,00514 claims
Mylan Inc.Atorvastatin Calcium$477,009$3,698589 claims
AbbVieSynthroid$51$1,70235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →